Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.3390/clinpract11040105

http://scihub22266oqcxt.onion/10.3390/clinpract11040105
suck pdf from google scholar
34940004!8700756!34940004
unlimited free pdf from europmc34940004    free
PDF from PMC    free
html from PMC    free
PDF vom PMID34940004 :   free

suck abstract from ncbi

pmid34940004
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Hormonal Contraception and Massive Pulmonary Embolism in a COVID-19 Ambulatory Patient: A Case Report #MMPMID34940004
  • Valenzuela-Vallejo L; Corredor-Orlandelli D; Alzate-Ricaurte S; Hernandez-Santamaria V; Aguirre-Ruiz JF; Pena-Pena A
  • Clin Pract 2021[Nov]; 11 (4): 914-918 PMID34940004show ga
  • Coronavirus 19 disease (COVID-19) presents a highly variable clinical presentation and course, ranging from asymptomatic patients to rapidly progressive, fatal pneumonia. The known heterogeneous outcomes can affect both previously healthy patients and those with significant comorbidities, who develop clinical courses with possibly more multisystemic compromise. Likewise, the development of thrombotic phenomena during the acute course of the disease is associated with complications that worsen patient prognosis. We present a case report of a 45-year-old multiparous patient with a history of overweight and chronic use of oral hormonal contraception with low doses of levonorgestrel and estradiol as the only risk factors favoring the development of thrombotic events. During her outpatient COVID-19 clinical course, she developed massive pulmonary thromboembolism resulting in secondary obstructive shock, which required pharmacological thrombolysis. At discharge, hormonal contraception was considered contraindicated, and the patient was released from our institution with continued oral anticoagulant therapy. COVID-19 infection, contraceptive hormone therapy, and overweight are known risk factors for the development of thromboembolic events. The impact of their concomitance has not been studied to date. From our experience, we discuss the impact these risk factors have when present together and invite others to report similar cases.
  • ä


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    914 4.11 2021